PositiveID Publishes Report on Its BioThreat Detection and Diagnostics Solutions

PositiveID Corporation Logo

DELRAY BEACH, Fla., Jan. 23, 2014 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today announced that it has published a report on the current market opportunities for its homeland security and medical diagnostics technologies.

"The bio-detection market has seen a surge in funding over the past decade," stated William J. Caragol, Chairman and CEO of PositiveID. "This increase can be directly attributed to events that have occurred since the beginning of the 21st century such as the Anthrax scare in 2001, the SARS outbreak in 2003, the ricin letters in 2004, the H1N1 health crisis in 2009, and most recently the concern over Syrian and North Korean biological and chemical weapons programs."

Mr. Caragol continued, "The urgent requirement for public healthcare and homeland security agencies to institute an early detection system for bio-terrorist attacks and infectious disease outbreaks is at hand. PositiveID's technologies reduce the time to both detect the presence of a threat and diagnose affected persons, enabling the deployment of countermeasures and vaccines in a time frame where casualties and fatalities can be drastically reduced. Our products are capable of revolutionizing not only our nation's response to bioterrorism but also improving medical testing at the point of need."

A copy of the report is available on PositiveID's website at http://www.positiveidcorp.com/files/PositiveID_Market_Opportunities_2014-01-24.pdf.

About PositiveID Corporation

PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.

Statements about PositiveID's future expectations, including, without limitation, the likelihood that the Company's products are capable of revolutionizing not only our nation's response to bioterrorism but also improving medical testing at the point of need; and all statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to target the bio-threat detection and rapid medical testing sectors; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 28, 2012, as amended on May 4, 2012, and 10-Qs filed on November 16, 2012, August 20, 2012, as amended on September 12, 2012, and May 14, 2012, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT: PositiveID Corporation Allison Tomek 561-805-8000 atomek@positiveidcorp.com

Source:PositiveID Corporation